Funded by the Global Health EDCTP3 Joint Undertaking, a new €15.3 million project coordinated by Institut Pasteur brings together seven partners across four continents to advance clinical trials and prepare for the manufacturing of a chikungunya vaccine in Africa.

Institut Pasteur is launching ACT-CHIK (Accelerating Clinical Trials for CHIKungunya Vaccine in Africa), a major four-year research project funded by the Global Health EDCTP3 Joint Undertaking under the European Union's Horizon Europe program. With €15.3 million in EU funding, ACT-CHIK will advance the clinical development of MV-CHIK — a measles-virus-based chikungunya vaccine originally developed at Institut Pasteur — through a large-scale Phase Ib/III clinical trial in four African countries, while preparing for technology transfer to an African vaccine manufacturer.

Find out more